Comparative Pharmacology
Head-to-head clinical analysis: PHENERGAN VC versus PHYRAGO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PHENERGAN VC versus PHYRAGO.
PHENERGAN VC vs PHYRAGO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Phenergan VC is a combination of promethazine (a phenothiazine derivative with antihistaminic, sedative, antiemetic, and anticholinergic effects) and phenylephrine (a sympathomimetic amine that acts as a decongestant via alpha-1 adrenergic receptor agonism). Promethazine antagonizes H1 receptors, thereby suppressing allergic reactions and motion sickness. Phenylephrine causes vasoconstriction in the nasal mucosa, reducing congestion.
PHYRAGO is a monoclonal antibody that targets and neutralizes the activity of a specific inflammatory cytokine, thereby inhibiting downstream signaling pathways involved in immune-mediated inflammation.
10-20 mL orally every 4-6 hours as needed; each 5 mL contains 6.25 mg promethazine HCl and 5 mg phenylephrine HCl.
200 mg orally twice daily with food.
None Documented
None Documented
9-16 hours; prolonged in hepatic impairment.
Terminal elimination half-life is 6–8 hours in adults; may be prolonged in hepatic impairment (up to 15 hours).
Renal: 70-80% as metabolites; biliary/fecal: 20-30%.
Primarily hepatic metabolism; renal excretion of unchanged drug accounts for <5% of dose; fecal elimination of metabolites accounts for ~90%.
Category C
Category C
Antihistamine/Decongestant Combination
Antihistamine